medigraphic.com
Boletín Médico del Hospital Infantil de México

2005, Number 2

<< Back Next >>

Bol Med Hosp Infant Mex 2005; 62 (2)

Non-myeloablative stem cell transplantation in children and adolescents: A single institutional experience.

Ruiz-Argüelles GJ, Morales-Toquero A, Gómez-Rangel JD, López-Martínez B

Language: Spanish
References: 32
Page: 88-95
PDF size: 84.08 Kb.


ABSTRACT

Introduction. Bone marrow transplantation is a curative option in some children with diverse underlying diseases.
Material and methods. Using the “Mexican” protocol to conduct allogeneic non-myeloablative stem cell transplantation (NST), we have prospectively carried out, in a single institution, 26 allografts in 20 individuals aged 1 to 18 years. Patients with both malignant (acute lymphoblastic leukemia, acute myelogenous leukemia and chronic myelogenous leukemia) and non-malignant (aplastic anemia, Blackfan-Diamond syndrome and homozygous thalassemia) conditions were included. Median age of the patients was 9 years (range 1-18).
Results. Median follow-up time is 184 days (range 14-1 796). In 10 of 26 allograft (38%) acute graft versus host disease (GVHD) was observed, whereas chronic GVHD was present in 4 out of 19 (21%) grafts followed for 100 days or more. The 100-day mortality was 19% and 12 patients experienced a post-transplant relapse of the malignancy. The 1 796 day’s overall-survival was 44%.
Conclusions. We report our experience with non-myeloablative stem cell transplantation in children and adolescents with both malignant and non-malignant underlying hematologic conditions. Although the experience is limited our results are very promising; moreover, due to the diminished toxicity and reduced cost, this approach seems to be a good alternative to allograft these types of patients in developing countries.


REFERENCES

  1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematological diseases. Blood. 1998; 91: 756-63.

  2. 2.Garaventa A,Porta F, Rondelli R. Early deaths in children after BMT. Bone Marrow Transplantation Group of the Italian Association for Pediatric Hematology and Oncology and Gruppo Italiano Trapianto di Midollo. Bone Marrow Transplant. 1992; 10: 419-23.

  3. Bearman SI, Appelbaum FR, Buckner CD. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988; 6: 1562-8.

  4. Pession A, Rondelli R, Paolucci P. Hematopoietic stem cell transplantation in childhood: report from the bone marrow transplantation group of the Associazione Italiana Ematologia Oncologia Pediatrica. Haematologica. 2000; 85: 638-45.

  5. Sanders JE. Growth and development after hematopoietic cell transplantation. En:Thomas ED, Blume KG, Forman SJ, editores. Hematopoietic cell transplantation. Malden: Blackwell Science; 1999. p. 764-75.

  6. Barret J, Richards C. Non-myeloablative stem cell transplants. Br J Haematol. 2000; 111: 6-17.

  7. Miniero R, Zecchina G, Nagler A. Non-myeloablative allogeneic stem cell transplantation in children. Haematologica. 2000; 85 Suppl 11: 12-7.

  8. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú O, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.Am J Hematol. 2001; 66: 241-4.

  9. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OG, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant. 2000; 25: 131-3.

  10. Giralt S, Estey E, Albitar M, van Besien K. Engraftment of allogenic hematopoietic progenitor cells with purine analogcontaining chemotherapy: harnessing graft versus leukemia without myeloablative therapy. Blood. 1997; 89: 4531-6.

  11. Khouri IF, Keating M, Korbling M, Przepiorka D,Anderlini P, O´Brien S, et al.Transplant-lite: induction of graft versus malignancy using fludarabina-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998; 16: 2817-24.

  12. Childs R, Contentin N, Clave E, Bacechi E, Hensel N, Boland C, et al. Reduced toxicity and transplant related mortality following non-myeloablative peripheral blood stem cell transplantation for malignant disease. Blood. 1999; 94 Suppl 1: 393a.

  13. Ruiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin. 1992; 50: 735-43.

  14. Ruiz-Argüelles A, Orfao A. Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. En: Ruiz-Argüelles GJ, San-Miguel JF, editor. Actualización en leucemias. México: Editorial Médica Panamericana; 1996. p. 79-82.

  15. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica. 2002; 87: 894-6.

  16. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. Proc Natl Acad Sci USA. 1996; 93: 2934-8.

  17. 17.Yam P, Petz L, Knowlton R,Wallace R, Stock A, deLange G, et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation. 1987; 43: 399-407.

  18. Ruiz-Argüelles GJ, López-Martínez B, Santellán-Olea MR, Abreu-Díaz G, Reyes-Nuñez V, Ruiz-Argüelles A, et al. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: A prospective study in a single institution. Leukemia Lymph. 2002; 43: 1509-11.

  19. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce-de-León S, Cantú-Rodríguez OG, Jaime-Pérez JC. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology. 2002; 7: 95-9.

  20. Ruiz-Argüelles GJ. “The Mexican approach” to conduct non-myeloablative stem cell transplantation. Eur J Haematol. 2001; 67: 5-6.

  21. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol. 2002; 76 Suppl 1: 376-9.

  22. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Llano O, Jaime-Pérez JC, López-Martínez B, et al. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transplant. 2003; 9: 157-61.

  23. Ruiz-Argüelles GJ, López-Martínez B, Gómez-Rangel D, Estrada E, Marín-López A, Bravo-Hernández G, et al. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen:A single institution experience. Hematology. 2003; 8: 151-4.

  24. Ruiz-Argüelles GJ, López-Martínez B, López-Ariza B. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin´s disease following autologous stem cell transplantation. Arch Med Res. 2003; 34: 242-5.

  25. Ruiz-Argüelles GJ. Trasplante alogénico no mieloablativo (TANM):La experiencia de Puebla y Monterrey.Gac Med Mex. 2003; 139 Suppl 2: S151-4.

  26. Ruiz-Argüelles GJ. Non-myeloablative bone marrow transplantation. Arch Med Res. 2003; 34: 554-7.

  27. Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S, González-Déctor L, Reyes-Núñez V, Garcés-Eisele J.The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol. 2004; 75; 200-4.

  28. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez Rangel JD, Vela-Ojeda J, Cantú-Rodríguez OG, Jaime-Pérez JC, et al.Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: A prospective study. Leukemia Lymphoma. 2004; 45: 1191-5.

  29. Ruiz-Argüelles GJ,Gómez-Almaguer D. Braking dogmata to help patients: Non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2004; 4: 1693-9.

  30. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD,Vela-Ojeda J, Karduss A, Cantú-Rodríguez OG, et al.Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with myeloid leukemias: Results of a prospective study of the Latin American Cooperative Onco Hematology Group (LACOHG).Blood. 2004; 104 Suppl 1:373b.

  31. 31.Jacobson DA,Duerst R,Tse W,Kletzel M.Reduced intensity haemopoietic stem cell transplantation for treatment of non-malignant diseases in children. Lancet. 2004; 364: 156-62.

  32. 32.Svennilson J,Ringden O.Is it time to reduce toxicity by non-myeloablative conditioning for allogeneic stem cell transplantation in children? Pediatr Transplant. 2000; 4: 300-4.




2020     |     www.medigraphic.com